Literature DB >> 3918904

Characteristics of insulin receptors and insulin action in human myelogenous leukemia cell line K-562.

T Yamanouchi, T Tsushima, Y Akanuma, M Kasuga, H Mizoguchi, F Takaku.   

Abstract

Specific binding sites for insulin have been identified and characterized for the human erythroleukemia cell line K-562. The binding of [125I]-insulin to the cells increased as a function of time, reaching a maximum at 20 min when incubation was performed at 37 degrees C. The binding of [125I]-insulin was dose-dependently inhibited by insulin or proinsulin. Scatchard plot of the binding data was curvilinear, and the number of insulin receptors was approximately 39,000. Insulin at concentrations of 0.05-10.0 ng/ml stimulated CO2 production and DNA and protein synthesis in K-562 cells in a dose-dependent manner, indicating that the insulin binding sites are functionally important in mediating these biochemical events induced by insulin. Maximal insulin responses were elicited at concentrations of less than 5 ng/ml, when (at most) 10% of the insulin receptors were occupied. After binding to the cells, [125I]-insulin was degraded in a time- and temperature-dependent manner. As reported for other types of cells, unlabeled insulin also downregulated insulin receptors in K-562 cells. When the cells were incubated with 1 X 10(-7) M unlabeled insulin for 24 h, the number of insulin receptors decreased by 50% without a change of affinity. K-562 cells may be useful in studying the role of insulin receptors in cell functions induced by insulin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3918904     DOI: 10.2337/diab.34.4.347

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  1 in total

Review 1.  Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.

Authors:  R J Klement; M K Fink
Journal:  Oncogenesis       Date:  2016-02-15       Impact factor: 7.485

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.